PRODUCT LITERATURE

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial

---

SENIORS recruited patients aged 70 years or older with symptomatic HF, irrespective of ejection fraction, and randomized them to nebivolol or placebo. Patients (n ¼ 2112) were divided by tertile of estimated glomerular filtration rate (eGFR). Mean age of patients was 76.1 years, 35% of patients had an ejection fraction of .35%, and 37% were women resulting in a unique cohort, far more representative of clinical practice than previous trials. eGFR was
strongly associated with outcomes and nebivolol was similarly efficacious across eGFR tertiles. The primary outcome rate (all-cause mortality or cardiovascular hospital admission) and adjusted hazard ratio for nebivolol use in those with low eGFR was 40% and 0.84 (95% CI 0.67–1.07), 31% and 0.79 (0.60–1.04) in the middle tertile, and 29% and 0.86 (0.65–1.14) in the highest eGFR tertile. There was no interaction noted between renal function and the treatment effect (P ¼ 0.442). Nebivolol use in patients with moderate renal impairment (eGFR ,60) was not associated with major safety concerns, apart from higher rates of drug-discontinuation due to bradycardia.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Nevodio
Nebivolol
SENIOR Trial

Specific Detail Info

-

Statement of Responsibility

European Journal of Heart Failure (2009) 11, 872–880

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment